Highlights

  • Invion Limited (ASX:IVX) reported FY26 customer revenue of AUD 384,707.
  • The company recorded a net loss of approximately AUD 5.63 million for FY26.
  • Its Photosoft program includes cancer research and collaborations addressing other disease areas.
  • A September 2026 announcement addressed director loans and a proposed securities issue.

Invion Limited (ASX:IVX) is an Australian biotechnology company developing photodynamic therapy applications based on its Photosoft platform. Its FY26 report documents research expenditure, limited commercial revenue and continuing losses, while recent disclosures describe financing arrangements and collaborations intended to support clinical development. Shares were quoted at AUD 0.038 at the time of writing on 19 October 2026, reflecting an 11.77% rise during the day’s trading session.

Company Business

Invion focuses on treatments using photosensitising compounds that are activated by light. The Photosoft technology is being researched for use in oncology and other therapeutic indications rather than being presented as an established source of medicine sales. Its development activities include preclinical testing, clinical investigation, regulatory preparation and work with research or commercial partners.

Its principal clinical and research program includes INV043, a photosensitising agent being assessed in different formulations and applications. In cancer research, the company has worked on skin lesions and the potential use of intravenous INV043 for oesophageal cancer. The business relies on licensed intellectual property, specialist scientific expertise and collaboration arrangements to progress these programs. Treatment efficacy and regulatory authorisation must be established through the relevant research and approval processes.

Recent Development

In September 2026, Invion disclosed director loan arrangements and a proposed issue of securities. These announcements are relevant to the company’s funding and capital structure, but a proposed issuance is not equivalent to completed funding. In mid-October, Invion also lodged an application for quotation of securities, extending the sequence of capital-related disclosures.

The company’s earlier operational announcements outline several research streams. In April 2026, Invion reported an expansion of its skin-cancer investigation to basal cell carcinoma patients following preliminary findings from other lesions. Preliminary observations are not equivalent to the outcomes of a completed pivotal trial or regulatory approval.

In May, Invion announced a partnership with SANGMYUNG Innovation concerning potential Photosoft applications in eye diseases. The company had also described cooperation with Hanlim Pharm involving preclinical work and regulatory preparation for an oesophageal-cancer program, with support associated with a Korean government-backed development initiative. The pace and scope of each project depend on the stipulated research milestones and partner activities.

Invion announced the appointment of a clinical adviser specialising in photodynamic therapy in June and a board appointment in August. These changes broaden the personnel involved in oversight and clinical planning, without establishing a timetable for commercial sales.

Financial Performance and Sector Context

For the financial year ended 30 June 2026, Invion reported customer revenue of AUD 384,707 and a loss after income tax of AUD 5,632,977. Research and development expenses were approximately AUD 1.48 million, while employee benefits expenses were around AUD 526,513. These figures illustrate a business still allocating resources to development rather than generating sufficient revenue to cover its operating costs.

At 30 June 2026, total assets were AUD 8.17 million and net assets were AUD 5.32 million. The annual report recorded accumulated losses of approximately AUD 148.81 million. These balance-sheet measures should be considered alongside cash requirements, subsequent securities transactions and the expenditure needed to advance research programs.

Photodynamic therapies operate within a regulated healthcare environment. Clinical trial design, safety findings, treatment efficacy, manufacturing standards, intellectual-property rights and regulatory review affect development pathways. Partner-funded research can reduce direct expenditure on individual projects, but the scope of funding and responsibility varies between agreements.

Risks to Consider

Invion faces clinical and regulatory execution risk because investigational treatments may not demonstrate the evidence required for approval. Development timelines can change with patient recruitment, research results and regulator feedback. Continued losses create financing needs, while additional equity or convertible instruments can affect the share count and existing ownership interests. The company also depends on licensed technology, counterparties and specialist research capabilities.

What to Watch Next

The next areas to monitor include the quarterly cash-flow report, updates on INV043 preclinical work, the skin-cancer research program, progress under the SANGMYUNG and Hanlim arrangements, and announcements concerning director loans or securities issues. Evidence of completed study milestones and the amount of cash available to fund operations will be more informative than collaboration announcements alone.

Key Insights

Invion’s FY26 results show a research-led company with modest revenue, a continuing net loss and a program spanning oncology and other potential Photosoft applications. Its financial position, clinical evidence and execution of partner agreements remain central to assessments of its operational progress.